Autoimmune Hemolytic Anemia

This is a specific type of hemolytic anemia where the body's own immune system attacks and destroys its red blood cells. This attack can be triggered by certain infections or medications. It causes anemia and can lead to fatigue.

Condition

What people with Autoimmune Hemolytic Anemia report

Every report comes from a Lived member, sent anonymously.

Have you tried Prednisone for Autoimmune Hemolytic Anemia?

NameHow it went

About Autoimmune Hemolytic Anemia

What It Is

Autoimmune hemolytic anemia (AIHA) is a rare condition in which the immune system makes antibodies against the body's own red blood cells. The antibodies mark those cells for destruction, so they are broken down (hemolysis) far sooner than their normal lifespan of about 120 days. When the bone marrow cannot replace them quickly enough, the result is anemia: too few red blood cells to carry oxygen comfortably around the body. People with AIHA may feel tired, weak, short of breath or dizzy, and their heart may pound or race. Because broken-down red cells release pigments, the skin and whites of the eyes can turn yellow (jaundice) and urine can look dark. The condition can develop slowly and stay mild, or come on quickly and become serious. There are two main forms, and the difference shapes treatment. Warm AIHA, the most common, involves antibodies that act at normal body temperature. Cold agglutinin disease involves antibodies that act in cooler temperatures, making red cells clump and break down; cold exposure can also turn fingers, toes, ears or nose painfully blue or white.

Causes & Risk Factors

In about half of people with warm AIHA, no underlying cause is found; this is called primary or idiopathic AIHA. In the rest, it develops alongside another condition that unsettles the immune system. Common examples include lupus and other autoimmune diseases, blood cancers such as chronic lymphocytic leukemia and lymphoma, some infections, problems with immune function, and stem cell transplants. Certain medicines can also trigger it, including some cancer immunotherapies. Cold agglutinin disease mostly affects adults over 40, with symptoms usually starting in later life. In its primary form it is driven by a small, abnormal group of antibody-making cells in the bone marrow. A similar cold antibody reaction can also follow infections such as mycoplasma pneumonia or mononucleosis, where it is often temporary. AIHA is not caused by anything a person did, and it is not inherited in a simple way. Finding a secondary cause matters, because treating that condition can be part of controlling the anemia.

How It's Diagnosed

Diagnosis starts with a blood count showing anemia, then tests that show red cells are being destroyed. A high reticulocyte count (young red cells released as the marrow tries to keep up), a raised bilirubin and LDH (lactate dehydrogenase, an enzyme released from damaged cells) and a low haptoglobin (a protein used up as it binds free hemoglobin) together point to hemolysis. The key test is the direct antiglobulin test, also called the direct Coombs test. It detects antibodies or immune proteins stuck to the surface of red cells, which shows the destruction is immune-driven. More detailed versions of this test, along with a cold agglutinin test, help tell warm AIHA from the cold form. A small number of people have AIHA with a negative Coombs test, which can make diagnosis slower. Because AIHA is often secondary, clinicians also look for an underlying cause. Depending on the person, that can mean tests for autoimmune disease or infection, a review of medicines, imaging, blood protein tests, or a bone marrow examination to look for a blood cancer.

Treatment Options

Treatment depends on the form, how severe the anemia is and whether another condition is driving it. Mild AIHA without troublesome symptoms may simply be watched. When a secondary cause is found, treating it is a central part of the plan. For warm AIHA, the first treatment is usually a steroid such as prednisone, which calms the immune attack. Most people improve within weeks, and the dose is then tapered slowly. Relapse is common, and long courses of steroids bring their own problems, such as raised blood sugar, bone thinning, weight gain and mood or sleep changes. Rituximab (Rituxan), an antibody infusion that removes the immune cells making the harmful antibodies, is the preferred next step and is sometimes added early in severe cases. Other immune-suppressing medicines, such as azathioprine or mycophenolate, and surgery to remove the spleen (splenectomy) are now usually reserved for later. Newer targeted drugs are being studied in clinical trials. Cold agglutinin disease is treated differently, and steroids are not the usual first choice. Keeping warm, especially the head, face, hands and feet, reduces red cell destruction and circulation symptoms, and hospitals warm intravenous fluids and blood for these patients. When treatment is needed, options include rituximab, sometimes combined with the chemotherapy drug bendamustine (relapses after rituximab are common but can be treated again), or sutimlimab (Enjaymo), an infusion that blocks the part of the immune system (complement) that destroys the antibody-coated cells. Hemolysis can return if sutimlimab is stopped, and because complement helps fight certain bacteria, vaccinations are needed before starting. Blood transfusions can be lifesaving when anemia is severe, but matching blood is harder because the antibodies react with donor cells, so blood banks need extra time and testing. During severe hemolysis, a preventive blood thinner may be used because the risk of blood clots rises. Steroids, other immune-suppressing drugs and splenectomy all increase the risk of serious infection, which shapes how treatment is chosen and monitored.

What to Expect

AIHA varies widely. Some people have a single episode that responds to treatment and does not return. Others have a long-term, relapsing course, with periods of good control interrupted by flares. Fatigue can linger even when blood counts improve, and it is a common complaint over the long term. Follow-up involves regular blood tests to track hemoglobin and markers of red cell destruction, especially while medicines are being reduced. Many people spend months tapering steroids, and the care team watches for side effects such as high blood sugar, bone loss and infection. Before or after a splenectomy, or when starting a complement inhibitor, specific vaccinations are usually needed. With cold agglutinin disease, daily life often involves planning around the cold: dressing warmly, limiting cold exposure, and telling other clinicians so that fluids and blood can be warmed during hospital care. If AIHA is linked to another condition, its course often follows how well that condition is controlled. Many people do well over the long term, although outcomes are generally worse when AIHA is secondary to another disease, particularly cancer.

When to Seek Help

See a clinician if you have unexplained tiredness, shortness of breath on exertion, a pounding heartbeat, pale or yellow skin, or dark urine, since these can all be signs of anemia and red cell destruction. If you already have AIHA, contact your care team promptly if dark urine or yellowing returns, tiredness clearly worsens, or you develop a fever or other signs of infection while taking steroids, other immune-suppressing medicines or a complement inhibitor, or after splenectomy. Get emergency care for chest pain, fainting, new confusion or severe shortness of breath, which can mean the anemia has become dangerously severe.

Questions to Ask Your Doctor

  1. 1.Is my AIHA the warm or cold type, and how does that change my treatment?
  2. 2.Have we looked for an underlying cause, and what would finding one change?
  3. 3.What is the plan for reducing my steroids, and what side effects should we watch for along the way?
  4. 4.What would we try next if the first treatment does not work or the anemia comes back?
  5. 5.Which signs of relapse or infection should I report, and how quickly?

Last reviewed • Oct 2026

Educational content, not medical advice.